A phase I trial of low-dose inhaled carbon monoxide in sepsis-induced ARDS

BACKGROUND. Acute respiratory distress syndrome (ARDS) is a prevalent disease with significant mortality for which no effective pharmacologic therapy exists. Low-dose inhaled carbon monoxide (iCO) confers cytoprotection in preclinical models of sepsis and ARDS. METHODS. We conducted a phase I dose e...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JCI Insight
Main Authors: Fredenburgh, Laura E., Perrella, Mark A., Barragan-Bradford, Diana, Hess, Dean R., Peters, Elizabeth, Welty-Wolf, Karen E., Kraft, Bryan D., Harris, R. Scott, Maurer, Rie, Nakahira, Kiichi, Oromendia, Clara, Davies, John D., Higuera, Angelica, Schiffer, Kristen T., Englert, Joshua A., Dieffenbach, Paul B., Berlin, David A., Lagambina, Susan, Bouthot, Mark, Sullivan, Andrew I., Nuccio, Paul F., Kone, Mamary T., Malik, Mona J., Porras, Maria Angelica Pabon, Finkelsztein, Eli, Winkler, Tilo, Hurwitz, Shelley, Serhan, Charles N., Piantadosi, Claude A., Baron, Rebecca M., Thompson, B. Taylor, Choi, Augustine M.K.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2018
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6328240/
https://ncbi.nlm.nih.gov/pubmed/30518685
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.124039
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados